Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
Eugene McLaurin,1 Mark Bergmann,2 Abhijit Narvekar,3 Adeniyi Adewale,3 Paul Gomes,4 Gail Torkildsen5 1Department of Ophthalmology, Total Eye Care, PA, Memphis, TN, 2Department of Ophthalmology, Apex Eye, Cincinnati, OH, 3Department of Ophthalmology, Alcon Research Ltd, Fort Worth, TX, 4Department o...
Enregistré dans:
Auteurs principaux: | McLaurin E, Bergmann M, Narvekar A, Adewale A, Gomes P, Torkildsen G |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/bcc1397ea6544626bbee7cd3c23cfce1 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies
par: Meier E, et autres
Publié: (2017) -
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
par: Malhotra RP, et autres
Publié: (2019) -
Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
par: Torkildsen G, et autres
Publié: (2015) -
Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
par: Mizoguchi T, et autres
Publié: (2017) -
Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
par: Meier EJ, et autres
Publié: (2018)